NeuBase Therapeutics, Inc.

NasdaqCM:NBSE 주식 보고서

시가총액: US$1.4m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NeuBase Therapeutics 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Todd Branning

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기2.3yrs
CEO 소유권0.04%
경영진 평균 재임 기간데이터 없음
이사회 평균 재임 기간3.5yrs

최근 관리 업데이트

Recent updates

Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

Aug 26
Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04

Aug 11

NeuBase Therapeutics promotes Dr. William Mann to President and COO

Jun 29

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

May 12
We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Jan 24
Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Oct 02
Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Jun 02
Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

Feb 23
Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

Jan 19
We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

NeuBase Therapeutics EPS in-line

Dec 23

NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy

Dec 16

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

Dec 15
Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

CEO 보상 분석

Todd Branning 의 보수는 NeuBase Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2023n/an/a

-US$25m

Dec 31 2022n/an/a

-US$30m

Sep 30 2022US$922kUS$311k

-US$34m

보상 대 시장: US 시장에서 비슷한 규모의 회사에 비해 Todd 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Todd 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.


CEO

Todd Branning (53 yo)

2.3yrs

테뉴어

US$922,445

보상

Mr. Todd P. Branning serves as an Interim Chief Executive Officer since January 16, 2024 and Chief Financial Officer of NeuBase Therapeutics, Inc. since January 2022 and serves as its Secretary. He joined...


이사회 구성원

이름위치테뉴어보상소유권
Dietrich Stephan
Founder4.8yrsUS$1.15m6.14%
$ 87.1k
Dov Goldstein
Independent Chairperson4.8yrsUS$74.42k0.040%
$ 567.0
Eric Richman
Independent Director4.8yrsUS$68.38k0.060%
$ 849.3
George Church
Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Boardless than a year데이터 없음데이터 없음
Steven Dowdy
Member of Gene Editing & Scientific Advisory Board4.6yrs데이터 없음데이터 없음
James Coull
Member of Gene Editing Advisory Boardless than a year데이터 없음데이터 없음
Randy Davis
Member of Scientific Advisory Board3.5yrs데이터 없음데이터 없음
Danith Ly
Member of Advisory Boardno data데이터 없음데이터 없음
Robert Friedlander
Chair of Scientific Advisory Boardno data데이터 없음데이터 없음
Peter Nielsen
Member of Gene Editing & Scientific Advisory Board3.6yrs데이터 없음데이터 없음
Eriks Rozners
Member of Gene Editing & Scientific Advisory Board3.5yrs데이터 없음데이터 없음
Gerald Mcdougall
Independent Director3yrsUS$59.79k0%
$ 0

3.5yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: NBSE 의 이사회경험(평균 재직 기간 3.5 년)으로 간주됩니다.